1021 - 1030 of 8620 Results
Title
Year
- The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism2021OPENTitle: The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonismJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-021-00162-1Best OA location URL: https://www.nature.com/articles/s41531-021-00162-1.pdfCitation Count: 18
- Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset2021RESTRICTEDTitle: Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmosetJournal Name: Naunyn-Schmiedeberg's Archives of PharmacologyPublisher: Springer Science and Business Media LLCVol: 394Issue #: 8Start Page: 1685End Page: 1692Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00210-021-02090-6Citation Count: 9
- Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset2021RESTRICTEDTitle: Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmosetJournal Name: Naunyn-Schmiedeberg's Archives of PharmacologyPublisher: Springer Science and Business Media LLCVol: 394Issue #: 12Start Page: 2381End Page: 2388Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00210-021-02162-7Citation Count: 3
- Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults2021OPENTitle: Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adultsJournal Name: Neurological SciencesPublisher: Springer Science and Business Media LLCVol: 43Issue #: 5Start Page: 3079End Page: 3087Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s10072-021-05784-0Best OA location URL: https://link.springer.com/content/pdf/10.1007/s10072-021-05784-0.pdfCitation Count: 7
- Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study2021OPENTitle: Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label StudyJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 2Start Page: 693End Page: 709Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00251-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00251-6.pdfCitation Count: 23
- Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease: A Retrospective Database Analysis2021OPENTitle: Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease: A Retrospective Database AnalysisJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page: 435End Page: 448Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00309-5Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00309-5.pdfCitation Count: 12
- Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia2021OPENTitle: Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and DyskinesiaJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 2Start Page: 739End Page: 751Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00256-1Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00256-1.pdfCitation Count: 11
- Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia2021OPENTitle: Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and DyskinesiaJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page: 307End Page: 320Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00246-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00246-3.pdfCitation Count: 13
- MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse Brain2021OPENTitle: MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse BrainJournal Name: NeurotherapeuticsPublisher: Elsevier BVVol: 18Issue #: 4Start Page: 2529End Page: 2540Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s13311-021-01130-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s13311-021-01130-6.pdfCitation Count: 20
- Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset2020RESTRICTEDTitle: Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmosetJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 182Issue #:Start Page: 108386End Page: 108386Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2020.108386Citation Count: 14